Genasense (Genta Inc).

摘要: Genasense (formerly known as G-3139), an antisense oligonucleotide specific for Bcl-2, is under development by Genta iv drip infusion the potential treatment of various cancers including melanoma, prostate, breast and colon cancer [3083751. It in phase III trials malignant which it has been awarded Fast Track status 1359044]. received Orphan Drug August 2000 [3782331. In September 2000, company announced that pivotal multiple chronic lymphocytic leukemia (CLL) acute myelocytic (AML) would be underway 2001 [382783]. By January 2001, AML CLL had initiated 1396512]. As February was planning initiation two additional, registration quality trials. Pending positive results from these trials, launch anticipated 2002 13984111. A trial patients with advanced myeloma at 65 centers US, Canada Great Britain began 2001. The will examine whether addition can improve response rates, duration life compared dexamethasone therapy alone 13989081. Inc issued a patent (US-05831066) 1283005]. provides protection to composition its analogs. Furthermore, also new patents cover series compounds containing backbone constructions enhance affinity drug target pre-RNA, while other covers methods preparation oligonucleotides structures 12896851. already licensed rights use Bd-2 antisense- gene therapy-based treatments University Pennsylvania. licensing agreements Chugai Pharmaceutical Co worldwide marketing profit sharing places favorable position. Needham & expected have market 47,700 melanoma US. analysts patient sizes 50,000 (CLL), 21,000 (AML), 136,000 (non-small cell lung cancer; NSLCC) 180,000 (prostate cancer) addition, predicted approved second quarter 2002, approvals follow (third 2002), 2002) (fourth 1399251].